BASEL, Switzerland, Dec. 19, 2017 /PRNewswire/ -- Roivant Sciences and HanAll Biopharma Co., Ltd. announced today that they have entered into a strategic collaboration and licensing agreement to develop, manufacture, and commercialize the anti-FcRn monoclonal antibody HL161 for the treatment of pathogenic IgG-mediated autoimmune diseases.
Under the agreement, HanAll will grant Roivant an exclusive license for the development, manufacture, and marketing of HL161 in the United States, Canada, Mexico, the European Union, the United Kingdom, Switzerland, Latin America, the Middle East, and North Africa. HanAll will receive a one-time upfront payment from Roivant, and will also receive research funding and milestone payments in line with future development progress as well as specified royalty payments after commercialization.
HL161 is a fully human monoclonal antibody targeting the neonatal Fc receptor (FcRn). Blockade of FcRn-Immunoglobulin G (IgG) interactions has been shown to lead to the rapid depletion of IgG. HL161 has potential as a treatment for IgG-mediated autoimmune diseases.
About HanAll Biopharma
HanAll Biopharma Co., Ltd., a subsidiary of Daewoong Pharmaceutical Co., Ltd., is a fully integrated biopharmaceutical company based in South Korea focusing on the discovery and development of innovative biological therapeutics in the areas of autoimmune diseases and immuno-oncology. HanAll's lead pipeline assets are 1) HL161, a fully human monoclonal antibody targeting neonatal Fc Receptor (FcRn) for the potential treatment of pathogenic-IgG mediated autoimmune diseases, 2) HL036, an anti-TNF ophthalmic solution for the treatment of dry eye diseases, and 3) two novel immuno-oncologic projects. HanAll's ambition is to be a leader in the area of immunology providing new therapeutics to patients with severe immune disorders in cooperation with specialized groups in each research field and through open innovation.
About Roivant SciencesRoivant is dedicated to transformative innovation in healthcare. Roivant focuses on realizing the full potential of promising biomedical research by developing and commercializing novel therapies across diverse therapeutic areas. Roivant partners with innovative biopharmaceutical companies and academic institutions to ensure that important medicines are rapidly developed and delivered to patients.
Roivant advances its drug pipelines through wholly- or majority-owned subsidiary companies, including Axovant (neurology), Myovant (women's health and endocrine diseases), Dermavant (dermatology), Enzyvant (rare diseases), and Urovant (urology). Roivant also pursues its mission by incubating and launching innovative healthcare companies operating outside of traditional biopharmaceutical development. Roivant's long-range mission is to reduce the time and cost of developing and delivering new medicines for patients. For more information, please visit www.roivant.com.